Lilly's Obesity Pipeline Progress Exceeds Expectations; Target Price Viewed at $1,283

Overview

This report summarizes key disclosures by Eli Lilly at the 47th Annual Global Healthcare Conference, focusing on obesity drug pipeline progress, market strategy, and financial outlook. Goldman Sachs maintains a Buy rating, stating that the company holds an advantage in a low-penetration market through its diversified product portfolio, with a target price of $1,283 implying 12.1% upside.

Core views

Obesity Market Strategy: Lilly emphasizes that the global obesity drug penetration rate is only about 3%, requiring education of the medical community, improved payment channels, and a richer product portfolio to unleash potential. The company's multi-asset layout outperforms competitors relying on single products, and it believes new product launches will not significantly cannibalize existing drug shares. Pipeline Product Progress: Retatrutide is positioned as a broad-spectrum patient drug; its 4mg dosage efficacy rivals Zepbound with simpler titration steps, marking the first time weight loss exceeds 20% in male patients. Eloralintide, as a non-GLP-1 mechanism drug, shows 17% weight loss and a vomiting rate of only 2% in Phase II data, suitable for 5-10% of GLP-1 intolerant populations. A Phase III trial combining tirzepatide results are expected in 2026. Long-acting formulation plans detail disclosure is expected in 2027. Commercialization Dynamics: Following the Foundayo launch, direct-to-consumer advertising has started, coverage by three major Pharmacy Benefit Managers (PBMs) is complete, and the Medicare channel opened in July. Overseas Mounjaro applications have been submitted in 45 countries, with international market share exceeding 50%; 75% of sales being cash payments indicates high willingness to pay. Financials and Valuation: Based on EPS forecasts for 2026-2028, a 28x P/E multiple yields a target price of $1,283. Current market cap stands at $1 trillion, with free cash flow yield expected to rise from 1.2% to 3.8%.

Analysis framework

Goldman Sachs employs penetration rate analysis and product portfolio strategies to evaluate market size, arguing for incremental potential by comparing different drug mechanisms (GLP-1 vs. non-GLP-1) covering patient groups. On valuation, it combines P/E multiples with cash flow forecasts, emphasizing the role of obesity business cash flows in supporting pipeline reinvestment. Risk considerations focus on pricing pressure, execution risk, and clinical data uncertainty.

Methodology notes

• Industry/Industrial Analysis FrameworkPenetration S-curve

  Obesity Drug Market Penetration Analysis

  Inferring the market is in its early stage based on current global penetration of 3%, calculating long-term growth space combined with patient base (billions of potential beneficiaries); this analysis is common in evaluating initial stages of high-growth industries.

• Competition and Strategy FrameworkProduct life cycle

  Multi-Asset Portfolio vs. Single-Product Competitors

  Lilly leverages a product portfolio including tirzepatide, retatrutide, and eloralintide to cover different patient needs, extending the market leadership cycle; this strategy is commonly used in the pharmaceutical industry to address patent expirations and intensifying competition.

• Valuation MethodPE/PEG valuation

  P/E Multiple Method

  Applying a 28x P/E multiple based on 2026-2028 EPS forecasts, reflecting a premium for high-growth certainty in the market; this method applies to mature pharmaceutical companies with stable earnings and strong growth visibility.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Eli Lilly & Co (LLY.US)

  Core beneficiary; obesity drug pipeline progress directly drives valuation

  Strengths

  Multi-asset portfolio covering different patient groups; manufacturing platform compatible with peptide drug production

  Weaknesses

  Risk of pricing pressure; uncertainty in overseas expansion execution

  Comparison

  Compared to competitors relying on a single GLP-1 product, product diversity reduces iteration risk

  Risks

  Clinical data falling below expectations; loss of market share

Key data

• Target Price$1,28312-month target price, implying 12.1% upside
• P/E Multiple28.0xBased on 2026-2028 EPS forecasts
• Obesity Market Penetration3%Current global treatment penetration rate
• Eloralintide Weight Loss Effect17%Phase II clinical data, vomiting rate 2%
• Mounjaro Overseas Share50%+International market share, 75% cash payment
• Free Cash Flow Yield1.2%→3.8%Forecast increase from 2025 to 2028

Impact & implications

The report argues that Lilly consolidates its leadership in the obesity market through differentiated product portfolios; retatrutide and eloralintide will expand markets for male patients and GLP-1 intolerant populations respectively. Accelerated overseas expansion and improved Medicare coverage are expected to drive short-term growth, while long-acting formulation layouts may reshape dosing frequency standards. The company's strong cash flow supports frequent M&A (one deal every 8-9 days), reinforcing synergies in pipelines such as oncology and neuroscience.

Risks

• Annual price cuts in the obesity market exceed expectations
• Market share falls below expectations due to external competition or internal execution failures
• Poor clinical data for pipeline assets triggers valuation multiple compression

What to watch

• Phase III trial results of eloralintide combined with tirzepatide (second half of 2026)
• Detailed disclosure of long-acting formulation plans (expected in 2027)
• Changes in prescription volumes after Foundayo obtains Medicare coverage
• Progress of listing applications in overseas 45 countries